Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Canatu, Webcast, Q4'25

By Inderes3/3/2026, 10:00 AM
Canatu

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Mari Makkonen
00:05 - 00:41

Hi everyone, and welcome to this news conference on Canatu's full year 2025 financial results. My name is Mari Makkonen, and I'm in charge of Investor Relations. Today our CEO Juha Kokkonen will begin with key messages. Then CFO Mikko Vesterinen will cover the key financials. And after that, Juha Kokkonen will return to discuss highlights and outlook. Following the presentations, you will have the opportunity to ask questions. You may type in your questions into the event chat already during the presentations. But without further ado, please go ahead.

Juha Kokkonen
00:42 - 08:53

Hi everyone, and welcome to this news conference on Canatu's full year 2025 financial results. My name is Mari Makkonen and I'm in charge of Investor Relations. Mari. Canatu is now, especially in the semiconductor domain, stronger than ever. There are four key points. We have now successfully deployed our first SEMI reactor to our customer, FST, which has made significant progress in validating its own product. And on top of that, we today announced that one of our existing customers has placed a purchase order with Canatu for long lead-time components for their second reactor. That way, they can secure product delivery at the time they need it for scaling their operations to the next level. Then we have strengthened the organization with new talent, both in the leadership team as well as throughout the organization. The industry, especially the semiconductor industry, is signaling a strong paradigm shift. Now, when advanced Semiconductor is moving to the two-nanometer node and starting next year, further towards A14 nodes. With that, we see high demand for CNT Pellicles. And overall, when it comes to all of these advanced applications where CNT is needed. Canatu's proprietary dry deposition process outperforms traditional CNT wet process. Our top line message today is that Canatu is in a strong competitive position and has built a solid foundation to capture customer opportunities. If you look at, firstly, the market drivers in the semiconductor domain, the artificial intelligence and especially advanced semiconductor ecosystem is on a strong and accelerating growth trajectory. Rising demand for advanced chips continues to drive adoption of high-power EUV scanners, driving new nodes like I was mentioning, two nanometer and as a next step, the A14 nanometer, to increase their power, reduce the energy consumption, and do things faster. And it is driving CNT Pellicles. On the automotive side, we do see two key drivers that are relevant for Canatu. The higher-level autonomous driving and assisted driving require an increasing number of sensors. For Canatu, the most relevant sensors are the camera sensors and those sensors with high optical requirements. Secondly, the thermal energy optimisation of battery electric vehicles through localized heating, such as window and windshield heating. And the next generation solar panels, where energy capturing capability will increase significantly from the current state, moving to the operational progress side. The first CNT100 SEMI reactor has been licensed to FST and is now ready for mass production of the CNT pellicle membranes. And this, of course, has been a very important foundation for companies, now that Canatu's solution, product, and technology is ready for mass production. We have also made progress in CNT pellicle validation, specifically full product validation with our partners. We have combined and deepened the relationship and technical discussions with major players in the ecosystem, including our existing customers, but with new customers as well. And this is supporting active negotiations on new orders, both existing like announced today and prospective customers. Then we have deepened our collaboration with DENSO, who has been our long-term partner, to improve CNT conductivity. That means, as an example, that windshield heating is happening faster and more efficiently. We have developed a large-scale chamber, overcoming our current 60-centimeter width limitation, to enable the scaling of production and the capability to address full windshield size, as well as solar cells. And these are very important for the future automotive applications. Then from the revenue perspective, Canatu's revenue has been growing for five years in a row, showing almost 100% growth until this year. And this year, that was a disappointment from the perspective that our revenue decreased by 24% in the second half and by 29% for the full year, amounting to 15.6 million. And the decline was mainly due to what we already communicated in our announcement in mid last year, which stated our expectation for reactor orders. If we had received those new reactor orders, the revenue would have been higher; and since there were no new reactor orders, that was the case. This revenue would have been small. As Canatu, over 90% of our revenue is coming from the five main customers. And these reactors are playing a key role at the moment there. So, this was the situation this year. Then we have been investing for growth. We have accelerated investments in medical diagnostics by creating an expert team and advancing technical capabilities, with clear focus on delivering ultra sensitive proof of concept, solution and alpha prototype for hormone testing this year. And this targets readiness for preclinical studies by the end of this year. We have built a business development team to create a solid pipeline of new high-value applications for our CNT. And with enhanced resources, we have strengthened our ecosystem collaboration and public funding to accelerate time to market. And then we have upgraded our manufacturing capability for higher volumes. We have been building our second factory so that the total production space will be over 5000m² and enabling multiple parallel reactor builds. So infrastructure is complete and the clean room remains on track for completion in first half of 26. And now I hand over to Mikko, our CFO, to cover key financials.

Mikko Vesterinen
08:56 - 13:05

And this has, of course, been a very important foundation, ensuring that Canatu's solution, product, and technology is now ready for mass production. As you mentioned, the revenue last year and in the second half declined on a year-on-year basis. And the drivers behind that were slower than anticipated customer approvals, which delayed both revenue recognition and then also had an impact on the follow-on reactor orders. Margin wise, our gross margin, despite the decline in revenue, increased. And that was driven by the changes in the revenue mix. So, a larger share of licensing based revenue and a lower share of reactor sales, among other things. At the same time. Adjusted EBIT decreased substantially, which was driven first and foremost by the decrease in revenue, but also due to our investments in future growth. We've been recruiting, and the headcount has increased on a full-time equivalent basis by 20% in the second half and by a similar percentage for the full year; capital expenditure increased in the second half by over 50% on a full-year basis. It remained on a similar level to full year 24. Our capital expenditure, by its nature, fluctuates between the half-years. And for instance, we announced last year an investment into a Pellicle membrane scanner, which was expected to arrive by the end of last year. But that was delayed until this year. This has an impact on our capital expenditure. Our Pelamis is now expected to arrive during H1 26. Despite the decline in revenue, our cash position and equity ratio balance sheet remains strong. And that obviously gives us some flexibility going forward still to invest in growth. And also a strong negotiation position. Then if we look at the revenue by business unit. Semiconductor business unit generated revenue of 10.8 million in Full-year 2025. Automotive, almost 5 million. So automotive grew very well year-on-year. And that growth was driven by strategic cooperation with Denso. First and foremost, on the Semiconductor side, the decline was driven by these reasons. We have already mentioned delay in customer approvals and lack of follow-on reactor orders. On the good side, we were able to complete the SAT for the first reactor last year. And then we also sold a commercial license to FST in the second half, and that was also fully recognized as revenue in the second half. Regarding inspection membranes, the revenue or demand decreased in absolute terms, but it continued to be a significant or considerable contributor to our revenue throughout the year 2025. And now I hand over back to you.

Juha Kokkonen
13:07 - 32:16

Thank you Mikko. I will then go to highlights and outlook. Firstly, I think that this is a familiar picture. I hope this is familiar to you. What is happening in the industry is that AI, mobile computing, and cloud computing are driving for better and more efficient nodes. So currently, two nanometer chips are ramped up, and the next node is 1.4 nanometer. I'm sorry, 1.4 nanometer. It's called A14. And what do we see there in the marketplace? And it also seems to be the industry consensus that this inflection point between composite pellicles and CNT pellicles is happening now, especially with this next node, which comes with higher power ASML scanners. However, we expect that Canatu CNT membranes and the pellicles made from them will be used for two nanometer technology. There was also a SPIE conference last week, the major advanced lithography conference, where ASML already showed and demonstrated their capability to increase power. The power was increased to the 1000-watt level. And that is, of course, very good news for us. And they actually thought that that could improve the throughput by 30% in 2030. So this roadmap could be even accelerated. Then our progress with our Korean customer FST. So FST is now the key industrial partner for Canatu, holding a commercial production license and operating our reactors there to manufacture CNT Pellicles. So, based on this membrane, they need to perform certain further steps, such as coating, inspection, and mounting it on the mask for semiconductor labs. And so we got this approval last summer. And then we got, they wanted to get a license for mass production in October 2025. They have made significant progress with the further steps where you need to then validate that one in EUV scanners, getting the third-party certification by ASML and getting the final certification by the end customers. It is public knowledge and news that FST has, for example, been selling pellicle inspection tools as well as pellicle mounting tools for the Samsung Taylor Factory in the USA, which will start to deliver and manufacture, for example, Tesla's AI chip. So based on this one, we do expect to start getting more consumable sales. But especially what will be very important for us is the royalties on each CNT pellicle that is sold by FST to the final customer. This is the familiar picture for you as well. We have covered where we are with FST and our Foundry Customer. We have recently made very significant progress there. And then the next key step is the Site Acceptance Testing for the first reactor on that site. And then, like I mentioned, we have had new reactor negotiations with existing customers. And we already announced that there is a purchase order for long lead time components to guarantee the reactor for the final definite agreement. Negotiations are still ongoing. We believe that our position in the marketplace, as communicated here, is significantly better compared to the time when we made these first contracts. Therefore, we have, of course, discussions there. How could we even improve the current terms that we have there. So, that takes some time. But the customer wanted to secure the timeline for this reactor deal. And then we are having discussions with new customers, as I have been telling, that I do see there can be in this market two, three, or at most four players. Now we have two customers here, and I think that there could be room, at least for one new player in this market when it comes to these nodes, based on new technology, that are larger than seven nanometers. There are four pellicle vendors. Moving on to the automotive side. Like Mikko mentioned, our automotive revenue grew and more than doubled last year. So the key driver for this has been Battery Electric Vehicles and the collaboration with DENSO. We have a long-term relationship there. And what our customers do see there is that there is a clear trend for energy optimization, for enhanced HVAC system. And that means heating, ventilation, air conditioning, and to provide localized heating. And especially now in our case, it means that windshield and side windows will be heated through localized film heating that will save significant energy and also enable significantly smaller HVAC systems, making the cockpit design significantly more living room-like. The second key element and driver here is next-generation solar panels, where their energy capturing efficiency could be improved by up to 40%. That is very significant compared to current technology, and that would be a possibility to extend range while parking a car in a sunny place. So this collaboration is very important, and we continue to make performance improvements. We have been developing this large-scale chamber that enables us to produce very sizeable CNT films for these solar panels as well as for the windshield. We are also targeting to improve productivity and cost through increased throughput by utilizing high-performance HPR reactors. This HPR stands for High Performance Reactor. Then on the medical diagnostic side, we are accelerating investments in ultra-sensitive, low-cost, scalable point-of-care diagnostics. Our aim is to become a leading point of care solution provider in hormones and infectious diseases, addressing the current sensitivity gap. So, the basic idea of this solution is: It is the same as hospital-level lab diagnostics, which take hours, if not days. Can be done in point of care in minutes in a cost-efficient manner, with almost no education required for the nurses to do this. That's the basic idea driving towards point of care. We have now demonstrated strong scientific progress with two published papers. And the third one is on peer review. And I really like this third one. It has not been published yet, but it is truly demonstrating the CNT capability and sensitivity benefit over competitive materials and technologies. Then we are going to strengthen capabilities by enhancing the development competencies, recruiting global talent. We have established the organization in USA in addition to our team in Finland. And a key task for this year is to integrate the proof of concept system and a functional alpha prototype for hormone detection, so that we can start preclinical tests already this year. As I have mentioned many times, most of the ideas for Canatu's applications using this most advanced CNT have come from our customers, such as Pellicles, inspection membranes, or heating elements. So now what we are building is a strong new business and product development team with dedicated experts. The idea is to accelerate the time to market for these high-value applications. Here are the key focus areas. What we focus on in microelectronics. Building on what we have done in the semiconductor domain, we are developing electrochemical sensing. Then, on top of this, medical diagnostics. And we are here leveraging public funding to accelerate the time to market for these high-value applications. Then, when we look at the financial outlook and this year, Canatu continues to see strong long-term potential in its three business focus areas: Semiconductor, Automotive, and Medical Diagnostics. But we decided that Canatu does not issue any specific numerical guidance for financial year 26. However, I'm going to cover this on the next slide. What are the key operational targets for 26? And based on that, you will understand pretty well what the target level is for our revenue this year and why we are not doing this one. The main reason is that we are in the middle of customer negotiations with our key customers for expanding reactor sales to go into this scale-up phase, as well as on the automotive side, having a big customer where deals have not been closed yet; and therefore we decided that it's better not to give this guidance, but we will give you very clear operational targets that we would like to achieve; then, when it comes to long-term targets, the Board of Directors has assessed and today decided to withdraw its previously communicated long-term financial targets of over €100 million in revenue and an EBIT margin of over 30% by 2027. And this is very much based on what we were already communicating in our last year's results, as well as what I was telling you about some delays with new customers and deals. And therefore, we came to the conclusion that we cannot achieve this €100 million revenue target next year. But we are going to give our new target in our Capital Markets Day on 26th of March. So now in three weeks' time. So then very important slide here. What are the key operational targets for 2026? So we say that we are having an extremely competitive position when it comes to our Pellicle technology. And we of course want to maintain and strengthen this position, secured last year through significant effort, both for reactor technology and for inspection membranes. Then we target to complete the customer approval for the second foundry customer and sell at least one new CNT100 reactor. And for the first one, we have already received the purchase order for long-lead-time items, so that based on Canatu technology, our customer will already start selling Pellicles. That will mean that we will start to get consumables, but especially royalties on CNT Pellicles sold, and then building our manufacturing capability so that we can build multiple parallel reactors in our factory in Finland, supporting both semiconductor and automotive production. The targets are to start mass production of ADAS camera heaters with a lead customer. Complete the joint development projects on CNT conductivity and large-scale chamber with our lead customer Denso. Next, we are advancing the development of the ADAS camera concept with enhanced material configuration in windshield glass. The basic idea there is that we will make integration of the Canatu CNT film easier, as well as more cost-efficient for windshield manufacturers to integrate that one inside the windshield, then continue developing full windshield heaters and next-generation solar cells with those enormous benefits. What they are, and as a new item, sell one high-performance CNT100 HPR, a high-performance reactor, to an automotive customer on the medical diagnostic side; we already very much covered this one to develop one integrated proof-of-concept system and functional alpha prototype for hormone monitoring. Publish scientific papers to build strong proof of concepts and proof points for that one. On business development side, we have received a lot of new application candidates from the ecosystem. So we want to evaluate at least ten new applications and identify the most promising business cases, primarily from microsystems and electrochemical sensing domains. And as you remember, this Canatu CNT material, where we are making the most advanced CNTs, that's like silicon. So you can do various applications based on that one. And our system is like a platform that you can easily build new applications without significant new investments there. And then we target to start one new development agreement with a credible significant industry player. In summary, our key message is that Canatu has a strong competitive position and solid foundation to capture customer opportunities. AI and advanced semiconductor ecosystem is strong and accelerating growth. This is rising demand for advanced chips for high power scanners, new nodes and thus also for CNT pellicles. On automotive side, assisted driving requires high optical requirements, especially for the camera sensors. Thermal energy optimization requires new types of heating solutions, localized heating, and enabling next-generation applications to extend the range of cars. Operational progress has been significant there. So we have proven our technology capability for EUV and Pellicles. We have made significant progress with the key industry partners, with our existing ones and with the new ones there, so that this supports active negotiation on new orders, both existing (as announced today) and prospective customers. We have deepened collaboration with Denso to improve our conductivity and develop large scale chambers. We are investing for future growth in the medical diagnostic domain to develop new solid application domains to accelerate time to market. And we are currently expanding our manufacturing capability to build multiple parallel reactors in our factory in Finland. As a summary, Canatu has gained momentum and strengthened its competitive edge in CNT Pellicles and continues to invest in future growth. Thank you.

Mari Makkonen
32:21 - 32:27

Thank you Juha. And now it's time for questions. Let's start with questions from the audience here in the room.

Arthur
32:29 - 32:47

Hi. It's from Inderes. Let's start with the semiconductor sector. First question about the second reactor customer that is still in the SAT process. Has there been any new delays with the customer and what kind of visibility do you have for the situation?

Juha Kokkonen
32:47 - 32:54

Yes, we have a very, very good visibility and there has not been any further delays with that one.

Arthur
32:55 - 33:11

Okay. Then about the FST and the royalties that are coming maybe this year. So are you expecting meaningful royalties already this year when the mass production starts? Or can you say anything about that?

Juha Kokkonen
33:14 - 33:43

I think that we don't have very good visibility on that one. So, what will be the volumes there? I think they would be in a range that is not yet super meaningful. I would say that because there will be a ramp-up phase, and the first Pellicles will be used. But I think that they will be super important for us.

Arthur
33:44 - 34:01

And can you say anything about CNT? Pellicles' price levels on the overall market? And then think about the price of the pellicle, and then the royalty that you're getting from the Pellicles or anything on that topic.

Juha Kokkonen
34:02 - 34:58

I think we don't have visibility on our customers' contracts there. If you think about what we do know, and it's very much like public information, composite pellicle prices vary roughly between 35,000 to 50,000 USD. So that's the range. Of course, with CNT Pellicles that's providing more value. You get better throughput using the CNT Pellicles. Of course, then it will be the question of what the competition will be. If there will be only these two players, there will be very little competition. And then the position of the players will be, of course, extremely good. If there will be more players, then there will be more competition, and that might affect the pricing.

Arthur
35:00 - 35:12

So are you expecting meaningful royalties already this year when the mass production starts? Then, are you still expecting customers to start using CNT pellicles in EUV machines with power less than 600W?

Juha Kokkonen
35:13 - 35:14

Yes.

Arthur
35:14 - 35:33

Yes. So no changes there. And then you're targeting to sell. At least one new SEMI reactor this year. And if we think about the key reasons that have been postponing the sales of new reactors, could you highlight those reasons?

Juha Kokkonen
35:34 - 36:56

I think the key reasons mostly occurred last year. So, as we delivered these reactors in 2024. So it has been taking time for our customers to first of all, get approval for the reactor and the Canatu delivery. But at the same time, they are developing the coating method so that this pellicle will last a long time. So the ASML target is like 10,000 wafers in the real scanner environment. So they are developing the coating on top of that one and then getting all the approvals for that one. You need to have an ASML approval so that your warranty of those scanners is valid. And then you need to get an approval from the foundry customer or the foundry itself. It can be when they are developing it so that it is ready for the process. That has been the key delay. But now I think that we are getting into a stage where the scaling will start. And that's very important that there has been the development time and then there has been the validation time, and now we are entering into this scaling time that's critical for us.

Arthur
36:57 - 37:07

Can you say anything about that? How much faster could you now deploy the second reactor, for example, to FST? Now when all of those different validations have been already done?

Juha Kokkonen
37:08 - 37:10

Significantly. Significantly.

Arthur
37:10 - 37:27

I think that what were the key reasons that mostly occurred last year. And you said that you are now targeting, when you have increased the capacity, to build multiple reactors at the same time. So can you say anything about how many reactors you are targeting to build at the same time?

Juha Kokkonen
37:28 - 37:51

No. We have our new factory and the room to build our capacity in such a way that we can address market demands. So whatsoever the market demand will be, we will have the capability to address that one.

Arthur
37:53 - 38:14

And regarding the revenue development in inspection membranes, I believe that in past years, you have mentioned that this business is growing. And now you said that the revenue declined. So what's the reason behind that? And are you still expecting that business to grow in the coming years?

Juha Kokkonen
38:15 - 40:13

In the long term, we do expect that business to grow. And the key thing there is that the customer. Let me have another example there. So there's one customer from the defect inspection market who launched a first product in 2005, and they were still selling last year, like tens of those equipments 20 years later. So we do expect the same thing to happen with EUV scanners, and these tools will be sold during the next ten, maybe even 20 years. So that will mean that the number of the tools will grow and grow and grow every year. The reason why there have now been lower sales than in earlier years. There are two main reasons. The first and key reason is that there has been a certain maintenance cycle for that tool, let's say 'X' days. And that has not been driven by Canatu inspection membrane but by some other element inside the tool. And now that some other element has managed to extend its maintenance cycle, basically doubling that one. So that has led into a situation that also our inspection filters are not changed as regularly as they used to be. But it has been expanded to double the time. So that has now for the time being lowered the demand there. But as the number of inspection tools again grows, we are then capturing the growth path there.

Arthur
40:14 - 40:26

You have discussed the potential to expand this business, for example, into optical filters and related applications. So how is that development going on?

Juha Kokkonen
40:27 - 40:35

We don't have today to announce any mass production product cases there yet.

Arthur
40:37 - 40:56

All right. And then still about the Competitive Position. You say now that there are two players on the market, so could you elaborate on the situation and how you perceive it? Is there any new competitors coming in or any different materials than CNT for the future? Pellicles.

Juha Kokkonen
40:58 - 42:05

If I'm starting with the latter one. So I just participated last week in San Jose, the SPIE conference. That is the leading yearly conference for advanced lithography. And there was one presentation about the future pellicles there, and that was with material called Beryllium. And then this beryllium material is extremely toxic. There are industry, very strong opinions that they will not accept beryllium as a material for pellicles. So that's the kind of thing. So from the competition perspective, we do see that CNT is something to prevail for as long as we have visibility here. Then what was your other question.

Arthur
42:05 - 42:11

About the current players in the CNT? I think that's the other one.

Juha Kokkonen
42:12 - 43:28

Then. We do know that Lintec has been developing. Their CNT pellicles, we haven't seen any traction from their efforts. They even asked whether Canatu could provide them CNT reactors. Canatu could sell them CNT reactors. So that is quite a strong indication of what their position is right now in the market. And then we, of course, do know that Mitsui has been trying to develop their CNT Pellicles; last year they announced that they would make a public announcement by end of last year, but that did not happen. Then. We do know also from public sources that that pellicle is non-coated. So you can think about what is then the lifetime of that pellicle. So, from that perspective, we can say that we are in an extremely strong position when it comes to our main business now, such that it will allow us to advance to next nodes and begin to scale.

Arthur
43:29 - 43:46

Then what was your other question. And then a couple of questions from the automotive side. You mentioned that you are targeting to deliver the first reactor for there also. So how that compares to the reactors in semiconductor business. And for example, from the revenue perspective.

Juha Kokkonen
43:48 - 45:38

I think that their approach is slightly different compared to the semiconductor domain. First, to provide some background for better understanding: when discussing applications like windshield heating or solar cells, we are potentially talking about millions of square meters. So a huge amount of CNT. And therefore, from the business model perspective, what we have been preliminarily discussing with our key partners is that Canatu would not be a player that operates factories globally, such as in Mexico and China. To develop this one. So the basic idea there is that this would be again, more like a licensing business rather than Canatu being a huge manufacturer of CNT pellicles and CNT films, and therefore, this is the first reactor we are negotiating to deliver to our key partner in this domain, so that they can start preparing their development, conduct further development there, and develop the production setup there. This is not yet targeted for mass production, this reactor. So that is a somewhat different approach compared to the semiconductor sector, for which these reactors are designed. For mass production.

Arthur
45:40 - 45:55

All right. And I think last year the revenue from the automotive side was mainly from those development projects with Denso and other projects under the hood. But are you expecting this year the automotive revenue to grow, or can you say anything about that?

Juha Kokkonen
45:56 - 45:57

Do you want to answer for that one?

Mikko Vesterinen
45:58 - 46:29

I think we will not comment about the actual outlook for automotive separately, but. We've been telling about this project and its future potential. So I think that the base is solid for this year. And there are key targets that we aim to reach this year. And if we are successful in those, it should be good.

Arthur
46:30 - 46:50

All right. And last question from me. Your headcount increased significantly last year. And what kind of recruitment or investment needs do you have for this year? Are you going to keep on going with the same pace with recruitments, even though your revenue expectations have been delayed compared to the listing?

Juha Kokkonen
46:51 - 47:29

I don't expect that we will grow as fast as we did last year because we made major investments, for example, in the Semiconductor business, where we really secured our competitive position. We made major investments in Medical Diagnostics. So we had a very small team, and we grew it as an additional factor. So those were the main headcount contributors there. And then we updated our management team. So I don't see a need for such a significant headcount increase this year.

Arthur
47:30 - 47:31

All right. But are you expecting this year the automotive revenue to grow, or can you say anything about that?

Mari Makkonen
47:31 - 47:44

Thank you, Arthur, for relevant questions. Let's then take a couple of questions from the chat. So first of all, are you going to publish new long-term financial targets in the upcoming CMD?

Juha Kokkonen
47:45 - 48:03

Yeah, we are right now working with our strategy. And we are developing our messages and will publish our long-term targets at the CMD.

Mari Makkonen
48:05 - 48:17

Then simple question. Mikko, how much of the €100 million that you received in conjunction with the listing deal have you used so far?

Mikko Vesterinen
48:18 - 48:38

At the end of the last financial year, our cash and short-term investments amounted to a total of 92 million. So? So the cash position was strong still.

Mari Makkonen
48:40 - 48:52

And then, what is your expectation of when the first recurring revenue will start coming in from the first CNT 100 SEMI reactor?

Juha Kokkonen
48:53 - 48:54

In this year?

Mari Makkonen
48:55 - 49:17

To Mikko, how much of the €100 million that you received in conjunction with the listing deal have you used so far? Then ASML introduced a roadmap where low NA EUV source power will increase over 600W. Will Canatu deliver pellicles to this application? And this is related to low NA EUV, not high NA application.

Juha Kokkonen
49:17 - 49:56

Now, first of all, for us and for the industry, it doesn't matter whether it's low or high NA. For both of those, it's relevant that the industry needs to move from conventional technology to CNT technology. Now with transitioning happening in this 500 to 600W level. And if you go further, our position is even better if you go to 800W or 1000W. So we do believe that our position there is even stronger compared to competition.

Mari Makkonen
49:58 - 50:09

So related to this, there's a follow-on question regarding Canatu CNT Pellicles. To Mikko, how much of the €100 million that you received in conjunction with the listing deal have you used so far? For 1000 or 1500 W EUV.

Juha Kokkonen
50:10 - 50:47

Of course it has not been tested, but basically the fundamental thing there is that CNT material is extremely heat tolerant. It is in a vacuum environment. It can tolerate up to 1500 Celsius. And this environment is a vacuum. So currently, the focal point operates at approximately 600 Celsius. So there is still a lot of headroom to go further.

Mari Makkonen
50:49 - 51:02

Then a question regarding investments. How do you justify delays in reactor orders and simultaneous investments in increasing production capacity?

Juha Kokkonen
51:04 - 51:25

We are now building this extra capacity to be ready by mid-this year, and I hope that it is coming exactly at the right time for being capable of making multiple reactors.

Mari Makkonen
51:27 - 51:49

Then going back to these NA 600 watt EUV systems. So how well received are CNT pellicles for these upcoming low Na 600 watt EUV systems? And are foundries eager or reluctant to adopt CNT pellicles for these production lines?

Juha Kokkonen
51:51 - 52:43

I think that we do see very high interest for that one. We do see, I had a very interesting discussion with one of the ASML executives just one week ago, and I think that the whole industry, including ASML and those foundries, is really welcoming this development because that enables them to use these higher power ASML systems, and that enables them to do even smaller nodes that are more powerful, more energy efficient, and so on. So I think that an ASML executive actually came to me to say, 'Hey, thank you.' Thank you for your progress.

Mari Makkonen
52:43 - 52:59

They're great. Then are you seeing any of your customers delaying negotiations due to Mitsui's plans of ramping up CNT Pellicles production during the first half of 2026?

Juha Kokkonen
53:00 - 53:02

No, I don't think so.

Mari Makkonen
53:03 - 53:14

Then, one question regarding the automotive. So in automotive, did your revenue grow solely due to Denso's development contract or did production sales volumes also grow?

Mikko Vesterinen
53:17 - 53:35

It was the key driver there. And of course, there were also other things behind the total number. But I think it's fair to say that the partnership with Denso expanded during the past year.

Mari Makkonen
53:37 - 53:43

Thank you. And do we have any final questions from the audience, or are we good? We are good.

Juha Kokkonen
53:46 - 53:51

Thank you. Thank you everyone. And Mari, do you want to cover this Capital Markets Day?

Mari Makkonen
53:51 - 54:08

Yes. Thank you. We will be hosting the Capital Markets Day on 26th of March at 10:00. 10:00, here at Sanoma Helsinki. And the registration is now open. So, please register on our investor site.

Juha Kokkonen
54:09 - 54:11

Thank you very much for your interest.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…